Preferences help
enabled [disable] Abstract
Number of results
2018 | 111 | 51-63
Article title

Contemporary management and novel therapies in ovarian cancer – literature review

Title variants
Languages of publication
Ovarian cancer is characterized by an extremely poor prognosis in women with an advanced stage of this carcinoma. In United States every year 20,000 women are diagnosed with ovarian cancer. It is the fifth most frequent cause of death from cancer in females and the most common cause of death for 15 years after diagnosis in women with stage III-IV tumors. Among ovarian neoplasms the most frequent are surface epithelial-stromal tumors. Moreover, non-epithelial ovarian tumors are distinguished. This group matters 10% of patients with diagnosed ovarian tumors. Due to a huge variety of ovarian tumors, the following work focuses mainly on the current clinical treatment of the epithelial ovarian cancer. The following paper summarizes current clinical treatment of epithelial ovarian cancer, including surgical procedure, chemo- and immunotherapy including modern therapeutic approaches.
Physical description
  • Faculty of Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland
  • Faculty of Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland
  • Faculty of Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland
  • Faculty of Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland
  • Faculty of Biotechnology, University of Wroclaw, Fryderyka Joliot-Curie 14a, 50-383 Wroclaw, Poland
  • Department of Biological Sciences, Institute of Experimental Biology, University of Wroclaw, Kanonia 6/8, 50-328 Wroclaw, Poland
  • Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556, Wroclaw, Poland
  • Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556, Wroclaw, Poland
  • Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556, Wroclaw, Poland
  • [1] Zhou Y, Layton O, Hong L. Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis. J Cancer 9(17) (2018) 3016–3022.
  • [2] Kumar V, Cotran RS, Robbins SL, Perkins JA, Olszewski W. Robbins pathology, Elsevier Urban & Partner (2005).
  • [3] Tomao F et al. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res 32(1) (2013) 48.
  • [4] Dinkelspiel HE et al. Long-term mortality among women with epithelial ovarian cancer. Gynecol. Oncol. 138(2) (2015) 421–8.
  • [5] Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Beecham JB, Bonfiglio TA. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum. Pathol. 19(11) (1988) 1273–9.
  • [6] Heintz A et al. Carcinoma of the Ovary. Int. J. Gynecol. Obstet. 95 (2006) S161–S192.
  • [7] Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol. Oncol. 96(2) (2005) 520–530.
  • [8] Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? Gynecol. Oncol. 113(1) (2009) 86–90.
  • [9] Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod. Pathol. 18(S2) (2005) S61–S79.
  • [10] Troiano RN, McCarthy SM. Müllerian Duct Anomalies: Imaging and Clinical Issues. Radiology 233(1) (2004) 19–34.
  • [11] Yakushiji M, Tazaki T, Nishimura H, Kato T. Krukenberg tumors of the ovary: a clinicopathologic analysis of 112 cases. Nihon Sanka Fujinka Gakkai Zasshi 39(3), (1987) 479–85.
  • [12] Cramer DW, Welch WR. Determinants of Ovarian Cancer Risk. II. Inferences Regarding Pathogenesis. JNCI J. Natl. Cancer Inst. 71(4) (1983) 717–721.
  • [13] Couch FJ et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 9(3) (2013) e1003212.
  • [14] Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol. Biomarkers Prev. 4(2) (1995) 169–73.
  • [15] Cohen SA, Leininger A. The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.. Appl. Clin. Genet. 7 (2014) 147–58.
  • [16] Whittmore AS, Harris R, Itnyre J. Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case -Control Studies. Am. J. Epidemiol. 136(10) (1992) 1184–1203.
  • [17] Kurta ML et al. Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Cancer Epidemiol. Biomarkers Prev. 21(8) (2012) 1282–92.
  • [18] Diergaarde B, Kurta ML. Use of fertility drugs and risk of ovarian cancer. Curr. Opin. Obstet. Gynecol. 26(3) (2014) 125–9.
  • [19] Nowacka-Zawisza M, Forma E, Walczak M, Różański W, Bryś M, Krajewska WM. Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer. Med. Oncol. 32(11) (2015) 246.
  • [20] F. Xia et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc. Natl. Acad. Sci. 98(15) (2001) 8644–8649.
  • [21] Antoniou A et al. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am. J. Hum. Genet. 72(5) (2003) 1117–1130.
  • [22] Steinke V, Engel C, Büttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. Dtsch. Arztebl. Int. 110(3) (2013) 32–8.
  • [23] Watson P et al. The Clinical Features of Ovarian Cancer in Hereditary Nonpolyposis Colorectal Cancer. Gynecol. Oncol. 82(2) (2001) 223–228.
  • [24] Martín-López JV Fishel R. The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam. Cancer 12(2) (2013) 159–68.
  • [25] Vasen HFA, Watson P, Mecklin J, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116(6) (1999) 1453–1456.
  • [26] Bermejo JL, Büchner FL, Hemminki K. Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC. Ann. Oncol. 15(4) (2004) 598–604.
  • [27] Graham J, Graham R. Ovarian cancer and asbestos. Environ. Res. 1(2) (1967) 115–128.
  • [28] Cramer DW, Welch WR, Cassells S, Scully RE. Mumps, menarche, menopause, and ovarian cancer. Am. J. Obstet. Gynecol. 147(1) (1983) 1–6.
  • [29] Menczer J, Modan M, Ranon L, Golan A. Possible role of mumps virus in the etiology of ovarian cancer. Cancer 43(4) (1979) 1375–1379.
  • [30] Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19(1) (2000) 3–10.
  • [31] Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 49(13) (1989) 3670–4.
  • [32] Longo DL, Harrison’s principles of internal medicine. McGraw-Hill (2012).
  • [33] Áyen A, Jiménez Martínez Y, Marchal JA, Boulaiz H. Recent Progress in Gene Therapy for Ovarian Cancer. Int. J. Mol. Sci. 19(7) (2018).
  • [34] Wroński M, Kluciński A, Krasnodębski IW. Sister Mary Joseph Nodule. J. Ultrasound Med. 33(3) (2014) 531–534.
  • [35] Shoupe D. Handbook of gynecology (2017).
  • [36] Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 70(2) (2000) 209–62.
  • [37] Zanetta G et al. Conservative surgery for Stage I ovarian carcinoma in women of childbearing age. BJOG An Int. J. Obstet. Gynaecol. 104(9) (1997) 1030–1035.
  • [38] Eisenkop SM, Friedman RL, Wang HJ. Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective Study. Gynecol. Oncol. 69(2) (1998) 103–108.
  • [39] Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study. Gynecol. Oncol. 47(2) (1992) 159–166.
  • [40] Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients. Gynecol. Oncol. 71(3) (1998) 431–436.
  • [41] Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42(2) (1991) 146–50.
  • [42] Piccart MJ et al. Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results. J. Natl. Cancer Inst. 92(9) (2000) 699–708.
  • [43] du Bois A et al. A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer. CancerSpectrum Knowl. Environ. 95(17) (2003) 1320–1329.
  • [44] Francis P et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 12(11) (1994) 2301–8.
  • [45] Wei W, Li N, Sun Y, Li B, Xu L, Wu L. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer. Oncotarget 8(14) (2017) 23862–23870.
  • [46] Pujade-Lauraine E et al. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. J. Clin. Oncol. 28(20) (2010) 3323–3329.
  • [47] Levine EA et al. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J. Am. Coll. Surg. 218(4) (2014) 573–85.
  • [48] Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev. (2016).
  • [49] Willett CG et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10(2) (2004) 145–147.
  • [50] Sousa F, Cruz A, Fonte P, Pinto IM, Neves-Petersen MT, Sarmento B. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci. Rep. 7(1) (2017) 3736.
  • [51] Xiao B et al. HIF-1 contributes to hypoxia adaptation of the naked mole rat. Oncotarget 8(66) (2017) 109941–109951.
  • [52] Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol. Res. 136 (2018) 97–107.
  • [53] AbdElhameid MK, Labib MB, Negmeldin AT, Al-Shorbagy M, Mohammed MR. Design, synthesis, and screening of ortho- amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors. J. Enzyme Inhib. Med. Chem. 33(1) (2018) 1472–1493.
  • [54] Kazazi-Hyseni F, Beijnen JH, Schellens JHM. Bevacizumab. Oncologist 15(8) (2010) 819–25.
  • [55] Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J. Gastroenterol. 19(31) (2013) 5051–60.
  • [56] Simpkins F, Garcia-Soto A, Slingerland J. New insights on the role of hormonal therapy in ovarian cancer. Steroids 78(6) (2013) 530–7.
  • [57] Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J. Clin. Oncol. 35(10) (2017) 1103–1111.
  • [58] Hamblin MR, Mróz P. Advances in photodynamic therapy : basic, translational, and clinical. Artech House (2008).
  • [59] Kwiatkowski S et al. Photodynamic therapy – mechanisms, photosensitizers and combinations. Biomed. Pharmacother. 106 (2018) 1098–1107.
  • [60] Shishkova N, Kuznetsova O, Berezov T. Photodynamic therapy for gynecological diseases and breast cancer. Cancer Biol. Med. 9(1) (2012) 9–17.
  • [61] Saczko J et al. The effectiveness of chemotherapy and electrochemotherapy on ovarian cell lines in vitro. Neoplasma 63(3) (2016) 450–455.
  • [62] Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 72(12) (1993) 3694–700.
  • [63] Sersa G, Miklavcic D. Electrochemotherapy of tumours. J. Vis. Exp. 22 (2008).
  • [64] Michel O et al. Electroporation with Cisplatin against Metastatic Pancreatic Cancer: In Vitro Study on Human Primary Cell Culture. Biomed Res. Int. 2018 (2018) 1–12.
  • [65] Kulbacka J et al. Doxorubicin delivery enhanced by electroporation to gastrointestinal adenocarcinoma cells with P-gp overexpression. Bioelectrochemistry 100 (2014) 96–104.
  • [66] Kulbacka J, Nowak M, Skołucka N, Saczko J, Kotulska M. The influence of electroporation on in vitro photodynamic therapy of human breast carcinoma cells. Folia Biol. (Praha) 57(3) (2011) 112–8.
  • [67] Kotulska M, Kulbacka J, Saczko J. Advances in photodynamic therapy assisted by electroporation. Curr. Drug Metab. 14(3) (2013) 309–18.
  • [68] Kulbacka J et al. The Effect of Millisecond Pulsed Electric Fields (msPEF) on Intracellular Drug Transport with Negatively Charged Large Nanocarriers Made of Solid Lipid Nanoparticles (SLN): In Vitro Study. J. Membr. Biol. 249(5) (2016) 645–661.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.